Home > Boards > US Listed > Biotechs > MannKind Corp. (MNKD)

From the MNKD proboards -->>

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
TTIME Member Profile
Member Level 
Followed By 18
Posts 1,351
Boards Moderated 0
Alias Born 08/25/00
160x600 placeholder
MannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 9:00:00 AM
MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD GlobeNewswire Inc. - 9/19/2019 9:00:00 AM
MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/30/2019 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:08:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:05:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:02:50 PM
MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights GlobeNewswire Inc. - 8/7/2019 4:01:00 PM
MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One ... GlobeNewswire Inc. - 8/5/2019 9:00:00 AM
MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019 GlobeNewswire Inc. - 8/1/2019 5:02:20 PM
Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3 GlobeNewswire Inc. - 7/31/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/18/2019 9:11:39 AM
MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants GlobeNewswire Inc. - 7/18/2019 8:52:49 AM
MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients GlobeNewswire Inc. - 7/15/2019 9:00:00 AM
MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules GlobeNewswire Inc. - 7/11/2019 4:14:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 6:07:20 AM
MannKind to Present at the JMP Securities Life Sciences Conference GlobeNewswire Inc. - 6/12/2019 9:00:00 AM
MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions GlobeNewswire Inc. - 6/9/2019 2:00:00 PM
Afrezza® (insulin human) Inhalation Powder Approved in Brazil GlobeNewswire Inc. - 6/3/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:41:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:31:33 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:30:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:29:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:28:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:28:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:27:36 PM
TTIME Member Level  Wednesday, 02/14/18 02:49:38 PM
Re: Don Quixote post# 27520
Post # of 31687 
From the MNKD proboards -->>

Here are a few reasons why we are going up in price:

1)The new hire from Lilly who also just happens to be a prior Chief Scientist for the American Diabetes Association.

2)New institutional holdings showing FMR is back into MNKD to a tune of 1.8 million shares and Blackrock continues to add.

3)The photo of Mike at the private screening party with quite a celebrity, with connections and a nice net worth.

4)New data yet to be released on Afrezza

5)One Drop study

6)Recent negative press on insurance companies hitting the public eye.

I am sure there are many more reasons to add that only Mike knows at this point but the ones listed above should serve as all good reasons for upward price climb.

All my posts are in my opinion only,do your own DD and don't spend more then you can afford to lose
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist